SCHEMBL1663009

SCHEMBL1663009

CC(C)CC(=O)c1c(O)ccc2c(=O)n(-c3ccc(C#N)nc3)c(C(C)C)nc12

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 1/20 0.41
USP14 P54578 4/20 0.40
PIK3CD O00329 4/20 0.34
PIK3CB P42338 3/20 0.34
ESR1 P03372 1/20 0.33
ESR2 Q92731 1/20 0.33
KDM5B Q9UGL1 1/20 0.32
KCNH2 Q12809 1/20 0.32
HRH3 Q9Y5N1 1/20 0.32
PDE4B Q07343 1/20 0.32
PDE4D Q08499 1/20 0.32
PIK3R2 O00459 2/20 0.32
CTSB P07858 1/20 0.31
APLNR P35414 1/20 0.31
PIK3R1 P27986 1/20 0.31
PIK3CA P42336 1/20 0.31
PIK3CG P48736 1/20 0.31
CXCR3 P49682 1/20 0.30
SYK P43405 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1665975 0.91 TRPV1 (0.41) TRPV1USP14PIK3CDPIK3CBESR1
SCHEMBL1663876 0.83 TRPV1 (0.44) TRPV1USP14PIK3CDPIK3CBESR1
SCHEMBL27727685 0.81 TRPV1 (0.41) TRPV1USP14PIK3CDPIK3CBESR1
SCHEMBL27727677 0.79 TRPV1 (0.41) TRPV1USP14PIK3CDPIK3CBESR1
SCHEMBL5071512 0.79 TRPV1 (0.42) TRPV1USP14PIK3CDPIK3CBESR1
SCHEMBL1664057 0.78 TRPV1 (0.57) TRPV1USP14ESR1ESR2CXCR3
SCHEMBL27727667 0.76 TRPV1 (0.39) TRPV1USP14PIK3CDPIK3CBESR1
SCHEMBL1663721 0.74 TRPV1 (0.72) TRPV1USP14PIK3CDPIK3CBESR1
SCHEMBL1663064 0.74 TRPV1 (0.60) TRPV1USP14ESR1ESR2PIK3R2
SCHEMBL1665823 0.73 TRPV1 (0.59) TRPV1USP14PIK3CDESR1ESR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2305652-A2 Trisubstituted quinazolinone derivatives as vanilloid antagonists Novartis AG (CH) 2011-04-06 EP disclosed
US-20090082365-A1 Trisubstituted Quinazolinone Derivatives as Vanilloid Antagonists NOVARTIS AG 2009-03-26 US disclosed
EP-1963283-A2 TRISUBSTITUTED QUINAZOLINONE DERIVATIVES AS VANILLOID ANTAGONISTS Novartis AG (CH) 2008-09-03 EP disclosed
WO-2007065662-A2 TRISUBSTITUTED QUINAZOLINONE DERIVATIVES AS VANILLOID ANTAGONISTS NOVARTIS AG (CH) 2007-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090082365-A1 Trisubstituted Quinazolinone Derivatives as Vanilloid Antagonists TRPV1, TRPV3, TRPV5 TRPV1 1/4885USP14 3406/4885PIK3CD 1916/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.